Luisa Piccin

446 total citations
16 papers, 219 citations indexed

About

Luisa Piccin is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Luisa Piccin has authored 16 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Luisa Piccin's work include Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (4 papers) and Synthesis and biological activity (3 papers). Luisa Piccin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (4 papers) and Synthesis and biological activity (3 papers). Luisa Piccin collaborates with scholars based in Italy, France and Greece. Luisa Piccin's co-authors include Vanna Chiarion‐Sileni, Jacopo Pigozzo, L Campana, Simone Mocellin, Sandro Pasquali, Sara Valpione, Silvana Del Vecchio, Elide Matano, Vincenzo Damiano and Sara Pellegrino and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Luisa Piccin

14 papers receiving 218 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luisa Piccin Italy 5 167 69 53 31 30 16 219
Yuequan Shi China 10 170 1.0× 89 1.3× 60 1.1× 13 0.4× 43 1.4× 27 265
Silvana Acquafredda Italy 6 159 1.0× 94 1.4× 43 0.8× 19 0.6× 42 1.4× 8 237
Ryota Shibaki Japan 10 243 1.5× 188 2.7× 47 0.9× 13 0.4× 32 1.1× 23 316
Anne Sibille Belgium 9 137 0.8× 83 1.2× 28 0.5× 31 1.0× 53 1.8× 21 204
Takehiro Tozuka Japan 10 198 1.2× 156 2.3× 23 0.4× 17 0.5× 28 0.9× 33 249
Alexandre Wicky Switzerland 6 94 0.6× 43 0.6× 42 0.8× 11 0.4× 37 1.2× 16 164
Masayuki Shirasawa Japan 10 167 1.0× 108 1.6× 24 0.5× 16 0.5× 27 0.9× 25 213
Claude Chahine France 7 128 0.8× 29 0.4× 19 0.4× 38 1.2× 30 1.0× 21 176
Haocan Song United States 7 124 0.7× 74 1.1× 31 0.6× 11 0.4× 48 1.6× 10 233
Anas Alshawa United States 6 126 0.8× 57 0.8× 44 0.8× 63 2.0× 24 0.8× 11 232

Countries citing papers authored by Luisa Piccin

Since Specialization
Citations

This map shows the geographic impact of Luisa Piccin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luisa Piccin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luisa Piccin more than expected).

Fields of papers citing papers by Luisa Piccin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luisa Piccin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luisa Piccin. The network helps show where Luisa Piccin may publish in the future.

Co-authorship network of co-authors of Luisa Piccin

This figure shows the co-authorship network connecting the top 25 collaborators of Luisa Piccin. A scholar is included among the top collaborators of Luisa Piccin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luisa Piccin. Luisa Piccin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Cosci, Ilaria, Paolo Del Fiore, Jacopo Pigozzo, et al.. (2025). Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Pharmaceuticals. 18(8). 1235–1235. 1 indexed citations
2.
Helgadóttir, Hildur, Mariaelena Capone, Luisa Piccin, et al.. (2025). Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial.. Journal of Clinical Oncology. 43(16_suppl). 9522–9522.
3.
Rossi, Ernesto, Lorenza Di Guardo, Ester Simeone, et al.. (2025). Tebentafusp in metastatic uveal melanoma patients: Results of the Italian expanded access program.. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations
4.
Scaini, Maria Chiara, Jacopo Pigozzo, Luisa Piccin, et al.. (2024). A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance. npj Precision Oncology. 8(1). 78–78. 8 indexed citations
5.
Potjer, Thomas P., Paola Del Bianco, Antonella Vecchiato, et al.. (2024). Polygenic Risk Score Improves Melanoma Risk Assessment in a Patient Cohort from the Veneto Region of Italy. Biology. 13(11). 954–954.
6.
Pasello, Giulia, Aline S.C. Fabricio, Paola Del Bianco, et al.. (2024). Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients. Journal of Translational Medicine. 22(1). 242–242. 7 indexed citations
7.
Fasiolo, Laura Tiozzo, Luisa Piccin, Alessio Fabozzi, et al.. (2024). Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations. The International Journal of Biological Markers. 39(1). 9–22. 3 indexed citations
8.
Scaini, Maria Chiara, Luisa Piccin, Davide Bassani, et al.. (2023). Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants. International Journal of Molecular Sciences. 24(15). 12285–12285. 4 indexed citations
9.
Facchinetti, Antonella, Jacopo Pigozzo, Luisa Piccin, et al.. (2022). Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach. Cancers. 14(17). 4153–4153. 3 indexed citations
10.
Pasello, Giulia, Aline S.C. Fabricio, Paola Del Bianco, et al.. (2022). Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and non–small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 40(16_suppl). 2549–2549. 3 indexed citations
11.
Nicolè, Lorenzo, Rocco Cappellesso, Luisa Piccin, et al.. (2021). RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study. Frontiers in Oncology. 11. 728319–728319. 3 indexed citations
12.
Pellegrino, Sara, Rosa Fonti, Luisa Piccin, et al.. (2019). Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. Annals of Nuclear Medicine. 33(12). 937–944. 38 indexed citations
13.
Dell’Aversana, Serena, Milena Coppola, Valeria Romeo, et al.. (2019). Germ cell tumors in male patients without gonadal involvement: computed tomography/magnetic resonance imaging findings and diagnostic workflow. Quantitative Imaging in Medicine and Surgery. 9(12). 2000–2007. 3 indexed citations
14.
Pavan, Alberto, Lorenzo Calvetti, Alessandro Dal Maso, et al.. (2019). Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel). Annals of Oncology. 30. v45–v45. 1 indexed citations
15.
Valpione, Sara, Sandro Pasquali, L Campana, et al.. (2018). Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. Journal of Translational Medicine. 16(1). 94–94. 143 indexed citations
16.
Valpione, Sara, Sandro Pasquali, L Campana, et al.. (2015). Predictors of toxicity for metastatic melanoma patients treated with ipilimumab. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuequan Shi Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by Ryota Shibaki Breakdown of academic impact, for papers by Anne Sibille Breakdown of academic impact, for papers by Takehiro Tozuka Breakdown of academic impact, for papers by Alexandre Wicky Breakdown of academic impact, for papers by Masayuki Shirasawa Breakdown of academic impact, for papers by Claude Chahine Breakdown of academic impact, for papers by Haocan Song Breakdown of academic impact, for papers by Anas Alshawa
Rankless by CCL
2026